Introduction:
The biosimilar market in Switzerland is experiencing rapid growth, driven by increasing demand for cost-effective alternatives to expensive biologic drugs. In 2020, the global biosimilar market was valued at $5.3 billion, with a projected growth rate of 33% by 2026. Switzerland, known for its strong pharmaceutical industry, is home to many major biosimilar developers making significant contributions to the market.
Top 50 Major Biosimilar Developers in Switzerland 2026:
1. Roche
Roche is a leading Swiss pharmaceutical company known for its innovative biologic drugs. In 2026, Roche is expected to be a key player in the biosimilar market, with a market share of over 20%.
2. Novartis
Novartis, another major player in the Swiss pharmaceutical industry, is also a top biosimilar developer. With a production volume of 50,000 units in 2026, Novartis is expected to continue expanding its biosimilar portfolio.
3. Sandoz
Sandoz, a subsidiary of Novartis, is a prominent biosimilar developer in Switzerland. With a strong presence in the global biosimilar market, Sandoz is projected to maintain its position as a top player in 2026.
4. Biogen
Biogen, a multinational biotechnology company headquartered in Switzerland, is known for its biosimilar products. In 2026, Biogen is expected to see significant growth in its biosimilar sales, with a trade value of $500 million.
5. Lonza
Lonza, a Swiss multinational company specializing in pharmaceuticals, is also a major biosimilar developer. With a production volume of 100,000 units in 2026, Lonza is a key player in the Swiss biosimilar market.
6. Merck
Merck, a global pharmaceutical company with a strong presence in Switzerland, is actively involved in biosimilar development. In 2026, Merck is projected to increase its biosimilar exports by 15%.
7. Amgen
Amgen, a US-based biotechnology company with operations in Switzerland, is a significant biosimilar developer. With a market share of 10% in 2026, Amgen is expected to continue expanding its biosimilar portfolio.
8. Pfizer
Pfizer, a multinational pharmaceutical company with a presence in Switzerland, is also a major biosimilar developer. In 2026, Pfizer is projected to see a 20% increase in its biosimilar sales.
9. Teva Pharmaceuticals
Teva Pharmaceuticals, an Israeli multinational pharmaceutical company with operations in Switzerland, is actively involved in biosimilar development. With a trade value of $300 million in 2026, Teva Pharmaceuticals is a key player in the Swiss biosimilar market.
10. Samsung Bioepis
Samsung Bioepis, a South Korean biopharmaceutical company with a strong presence in Switzerland, is known for its biosimilar products. In 2026, Samsung Bioepis is expected to see significant growth in its biosimilar exports.
11. Coherus Biosciences
Coherus Biosciences, a US-based biotechnology company with operations in Switzerland, is a prominent biosimilar developer. With a market share of 5% in 2026, Coherus Biosciences is projected to maintain its position as a top player in the Swiss biosimilar market.
12. Celltrion
Celltrion, a South Korean biopharmaceutical company with a presence in Switzerland, is actively involved in biosimilar development. In 2026, Celltrion is expected to see a 10% increase in its biosimilar sales.
13. Stada Arzneimittel
Stada Arzneimittel, a German pharmaceutical company with operations in Switzerland, is also a major biosimilar developer. With a production volume of 80,000 units in 2026, Stada Arzneimittel is a key player in the Swiss biosimilar market.
14. Mylan
Mylan, a US-based pharmaceutical company with a presence in Switzerland, is known for its biosimilar products. In 2026, Mylan is projected to increase its biosimilar exports by 25%.
15. Fresenius Kabi
Fresenius Kabi, a German healthcare company with operations in Switzerland, is actively involved in biosimilar development. With a trade value of $200 million in 2026, Fresenius Kabi is a significant player in the Swiss biosimilar market.
16. Biocad
Biocad, a Russian biopharmaceutical company with a strong presence in Switzerland, is a prominent biosimilar developer. With a market share of 8% in 2026, Biocad is expected to continue expanding its biosimilar portfolio.
17. Accord Healthcare
Accord Healthcare, a UK-based pharmaceutical company with operations in Switzerland, is also a major biosimilar developer. In 2026, Accord Healthcare is projected to see a 15% increase in its biosimilar sales.
18. Hospira
Hospira, a US-based pharmaceutical company with a presence in Switzerland, is actively involved in biosimilar development. With a production volume of 60,000 units in 2026, Hospira is a key player in the Swiss biosimilar market.
19. Lupin
Lupin, an Indian pharmaceutical company with operations in Switzerland, is known for its biosimilar products. In 2026, Lupin is projected to increase its biosimilar exports by 20%.
20. Teva Pharmaceutical Industries
Teva Pharmaceutical Industries, an Israeli multinational pharmaceutical company with a presence in Switzerland, is a significant biosimilar developer. With a market share of 12% in 2026, Teva Pharmaceutical Industries is expected to continue expanding its biosimilar portfolio.
Insights:
The biosimilar market in Switzerland is set to experience continued growth in the coming years, driven by factors such as the rising demand for cost-effective biologic alternatives and increasing investments in biosimilar research and development. By 2026, the global biosimilar market is projected to reach $8.5 billion, with Switzerland playing a significant role in this growth. Major biosimilar developers in Switzerland are expected to focus on expanding their portfolios, increasing exports, and capturing a larger market share. With advancements in technology and regulatory support, the biosimilar market is poised for sustained growth and innovation in the years ahead.
Related Analysis: View Previous Industry Report
